Cetuximab in the treatment of advanced non-small cell lung cancer: FISHing for a miraculous catch

Lorenza Landi¹, Antonio Rossi²

¹Medical Oncology Department, AUSL della Romagna, Ravenna, Italy; ²Division of Medical Oncology, Scientific Institute for Research and Health Care (IRCCS) “Casa Sollievo della Sofferenza”, San Giovanni Rotondo (Foggia), Italy

Correspondence to: Antonio Rossi, MD. Division of Medical Oncology, Scientific Institute for Research and Health Care (IRCCS), Casa Sollievo della Sofferenza Hospital, Viale Padre Pio, 71013, San Giovanni Rotondo (FG), Italy. Email: arossi_it@yahoo.it.

Provenance: This is an invited Editorial commissioned by Section Editor Dr. Ming-Hui Zhang (Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China).


Submitted Mar 26, 2018. Accepted for publication Apr 16, 2018.
doi: 10.21037/jtd.2018.04.126
View this article at: http://dx.doi.org/10.21037/jtd.2018.04.126

Non-small cell lung cancer (NSCLC) is divided in two main histologies: non-squamous and squamous histotypes. In metastatic non-squamous NSCLC patients, the oncogene-addicted subgroups are characterized by the presence of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase 1 (ROS1) deregulations which can benefit, in the current practice, by specific tyrosine kinase inhibitors (TKIs). The programmed death-ligand 1 (PD-L1) ≥50% selects another subgroup which can benefit, in the clinical practice, by first-line pembrolizumab. In squamous NSCLC patients, the only biomarker able to select a group of patients who can benefit from a personalized therapy with pembrolizumab is that with strong positive PD-L1. Overall, about 60% of non-squamous NSCLC patients and approximately 75% of squamous ones still receive chemotherapy as first-line approach (1,2).

However, even in absence of mutations, EGFR overexpression on the surface of tumor cells can regulate cell proliferation and survival, representing the rationale to exploit alternative ways to inhibit EGFR axis through monoclonal antibodies (mAbs) such as cetuximab and necitumumab (3). The EGFR overexpression detected by immunohistochemistry (IHC) was found in approximately 80–90% of NSCLC patients regardless of histotypes (4). Based on this finding, several trials investigated anti-EGFR mAbs in combination with chemotherapy. An individual patient data meta-analysis included 2018 advanced NSCLC patients from four randomized phase II/III trials investigating the addition of cetuximab to first-line platinum-based chemotherapy. Median overall survival (OS) was 10.3 months for the cetuximab plus chemotherapy arm vs. 9.4 months for the chemotherapy alone [hazard ratio (HR), 0.88; P=0.009], the median progression-free survival (PFS) was 4.7 vs. 4.5 months (HR, 0.90; P=0.045) and the objective response rate (ORR) was 32.2% vs. 24.4% [odds ratio (OR), 1.46; P<0.001], respectively. The safety profile of the addition of cetuximab to chemotherapy resulted manageable. Overall, this meta-analysis indicated a favorable benefit/risk ratio for the addition of cetuximab to platinum-based, first-line chemotherapy for advanced NSCLC patients (5). However, regulatory authorities considered these data insufficient for recommending the approval, judging the OS benefit and risks as disproportional. Hence, the results observed clearly indicated that there was a consistent fraction of NSCLC patients deriving little or no benefit from cetuximab therapy, confirming the importance of a proper patient selection. In this context, EGFR overexpression might be crucial for cetuximab activity. In the largest FLEX trial, which enrolled only EGFR overexpressing NSCLC patients (6), the outcomes were evaluated according to EGFR expression and using a specific histoscore (H-score), demonstrating that the addition of cetuximab to chemotherapy produced a
significant benefit only in individuals with an EGFR score equal or greater than 200 (7). Nevertheless, H-score as well other IHC scoring systems resulted as weak predictors for cetuximab benefit, thus highlighting the need of a more reliable biomarker (8). However, interestingly, in the FLEX trial, the greatest OS improvement was obtained in patients with squamous cell histology (HR, 0.80), with an increased risk of adverse events, particularly febrile neutropenia (6).

Necitumumab was also investigated in phase III trials either in combination with pemetrexed and cisplatin without increasing OS of previously untreated metastatic non-squamous NSCLC patients (9) and in combination with gemcitabine and cisplatin, improving OS in patients with advanced squamous NSCLC patients (10).

Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF), in combination with paclitaxel and carboplatin, is one of the standard-of-care for first-line therapy of non-oncogene addicted non-squamous NSCLC patients (2).

EGFR gene copy number assessed by fluorescent in situ hybridization (FISH) and defined according to the Colorado Criteria, has proven, retrospectively, to be potentially useful for selection of NSCLC patients for cetuximab and necitumumab plus chemotherapy (11-14).

These considerations became the background for designing the South Western Oncology Group (SWOG) S0819 trial. Herbst et al. investigated the safety and effectiveness of first-line therapy with carboplatin plus paclitaxel with or without bevacizumab either with cetuximab or without in patients with advanced NSCLC. The trial was designed to validate the EGFR FISH assay as predictive biomarker for cetuximab benefit. The co-primary endpoints were OS in the whole study population and PFS in patients with EGFR FISH-positive, using the Colorado Criteria (15). A total of 1,313 patients were randomly assigned to the control group (n=657; 277 with chemotherapy plus bevacizumab and 380 with chemotherapy only) or to the cetuximab group (n=656; 283 with chemotherapy plus bevacizumab and 373 with chemotherapy only). Patients were allocated in the no-bevacizumab arms if they were unsuitable for bevacizumab due to medical reasons or physician opinion. EGFR FISH-positivity was detected in 400 patients (41%) out of the 976 assessable. In the total population, median PFS was 4.5 months in the control arm and 4.6 in the cetuximab group [HR, 0.99; 95% confidence interval (CI), 0.88–1.10; P=0.83], median OS was 9.2 and 10.9 months (HR, 0.93; 95% CI, 0.83–1.04; P=0.22) and ORR 36% vs. 42% (P=0.060), respectively. In the EGFR FISH-positive subpopulation, the median PFS was 4.8 vs. 5.4 months (HR, 0.92; 95% CI, 0.75–1.12; P=0.40) between the control group and the cetuximab group, respectively. Median OS was 9.8 vs. 13.4 months (HR, 0.81; 95% CI, 0.66–1.00; P=0.054) and ORR was 43% vs. 47% (P=0.48), respectively. Severe adverse events, mainly hematological toxicities, fatigue and skin rash occurred in 9% of patients in the cetuximab group and 5% of patients in the control group. Toxic deaths occurred in 6% of patients in the cetuximab group and 2% of patients in the control group. Bevacizumab was not associated with OS or PFS in the entire population or according to EGFR FISH status, with a moderate increase of toxicity (15).

However, the most compelling finding of the study emerged from a pre-specified subgroup analysis, looking at the potential impact of tumor histology on cetuximab outcome. In the EGFR FISH-positive subpopulation with squamous cell histology, median OS was 11.8 months in the cetuximab group and 6.1 months in the control group (HR, 0.58; 95% CI, 0.36–0.86; P=0.0071), although no difference in PFS was reported between these two treatment subgroups (median 4.5 vs. 2.8 months, respectively. HR, 0.68; 95% CI, 0.46–1.01; P=0.055). In patients with EGFR FISH-negative with squamous cell histology or patients with non-squamous histology regardless of EGFR FISH status, OS and PFS did not differ among control and cetuximab arms (15).

To date, the SWOG S0819 is the largest trial having a biomarker-driven co-primary end point. Furthermore, even if the study should be considered as a negative trial, it supports the conviction that tumor histology is more than a sum of morphological features, thus reflecting different tumor biology. Squamous cell carcinoma rarely harbors EGFR mutations while the EGFR overexpression is frequent, underlying both an EGFR dependence and a potential sensitivity to EGFR-inhibition (6,10,16). In the SQUIRE trial, addressed exclusively to squamous NSCLC, the addition of necitumumab to front-line cisplatin-gemcitabine translated into an improved OS with a median of 11.5 vs. 9.9 months (HR, 0.84; P=0.01) (10). A subgroup analysis showed a trend toward better PFS and OS for EGFR FISH-positive patients (17) (Table 1). Thus, SWOG S0819 and SQUIRE findings seem to apparently answer an important question: the optimal front-line therapy for advanced squamous NSCLC. However, in the clinical practice, we should perform the EGFR FISH assay in the presence of squamous histology in order to administer an anti-EGFR mAb in case of positivity. In this way, should
Table 1 Results of phase III trials of anti-EGFR monoclonal antibodies and chemotherapy in advanced NSCLC in overall population and according to EGFR FISH status

<table>
<thead>
<tr>
<th>Treatment</th>
<th>BMS 099 (8)</th>
<th>FLEX (6,7)</th>
<th>SQUIRE (10,17)</th>
<th>SWOG S0819 (15)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CBDCA/TXT or TXL</td>
<td>CBDCA/TXT or TXL + CET</td>
<td>HR and P</td>
<td>CBDCA/TXT or TXL</td>
</tr>
<tr>
<td>No. of pts</td>
<td>338</td>
<td>338</td>
<td>568</td>
<td>557</td>
</tr>
<tr>
<td>Outcome in overall population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORR, %</td>
<td>25.7</td>
<td>30.7</td>
<td>P=0.0066</td>
<td>29</td>
</tr>
<tr>
<td>PFS, months</td>
<td>4.24</td>
<td>4.40</td>
<td>HR, 0.9; P=0.2358</td>
<td>4.8</td>
</tr>
<tr>
<td>OS, months</td>
<td>8.38</td>
<td>9.69</td>
<td>HR, 0.89; P=0.1685</td>
<td>10.1</td>
</tr>
<tr>
<td>Outcome according to EGFR FISH status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORR, %</td>
<td>22.0</td>
<td>37.0</td>
<td>P=0.37</td>
<td>26.4</td>
</tr>
<tr>
<td>PFS, months</td>
<td>5.4</td>
<td>5.4</td>
<td>HR, 1.54; P=0.18</td>
<td>4.2</td>
</tr>
<tr>
<td>OS, months</td>
<td>8.6</td>
<td>12.5</td>
<td>HR, 1.92; P=0.03</td>
<td>9.9</td>
</tr>
<tr>
<td>ORR, %</td>
<td>16.7</td>
<td>30.8</td>
<td>P=0.33</td>
<td>34.7</td>
</tr>
<tr>
<td>PFS, months</td>
<td>4.3</td>
<td>3.8</td>
<td>HR, 0.65; P=0.15</td>
<td>4.2</td>
</tr>
<tr>
<td>OS, months</td>
<td>7.4</td>
<td>7.4</td>
<td>HR, 0.84; P=0.57</td>
<td>10.0</td>
</tr>
</tbody>
</table>

EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; NSCLC, non-small-cell lung cancer; No. pts, number of patients; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; NR, not reported; CBDCA, carboplatin; TXT, docetaxel; CET, cetuximab; CDDP, cisplatin; GEM, gemcitabine; VNR, vinorelbine; TXL, paclitaxel; NEC, necitumumab.
we consider the EGFR FISH-positive squamous cell carcinoma an addicted population? This is not correct, in fact, although it is a common opinion to consider a cancer population carrying a specific molecular event as target-driven, EGFR FISH-positive squamous cell lung carcinoma looks very different from the other addicted NSCLCs, mainly because so far, no anti-EGFR mAbs demonstrated activity when used alone in this subgroup. In addition, it is not possible to exclude that anti-EGFR benefit should be restricted to the EGFR amplified group only, thus reducing from approximately 40% to 7%—the amount of patients potentially benefiting from anti-EGFR mAb, as suggested by an analysis of granular EGFR FISH data from the SQUIRE trial (14). Finally, FISH assay has some limitations, including reproducibility, the need of tissue specimens and costs.

Considering that most of patients are still receiving first-line chemotherapy regardless of histology, the unmet need is to select other subgroups of patients who can benefit from a personalized treatment. The potential of EGFR FISH selection in squamous NSCLC is further complicated by the introduction of immunotherapy, which is radically changing the treatment landscape of NSCLC. In fact, on 20th March 2018, a press release announced that the phase III IMpower131 trial met its co-primary end point of PFS, still waiting for the final OS results. The trial demonstrated that the combination of atezolizumab, an anti-PD-L1 mAb, to carboplatin plus nab-paclitaxel reduced the risk of PFS and death compared to chemotherapy alone as first-line treatment of advanced squamous NSCLC patients, regardless of PD-L1 expression (18).

In conclusion, SWOG S0819 results should be not sufficient to find a place for cetuximab in the treatment algorithm of advanced NSCLC, even in squamous histology and in EGFR FISH-positive patients. Additional studies specifically focused on EGFR FISH amplified population are strongly encouraged to definitively address the role of anti-EGFR mAb in such setting and possibly explore the potential of combining anti-EGFR mAbs strategies with immunotherapy.

Acknowledgements
None.

Footnote
Conflicts of Interest: Antonio Rossi is Speaker Bureau for Eli Lilly, MSD, Boehringer Ingelheim, AstraZeneca, Roche. The other author has no conflicts of interest to declare.

References


